For the quarter ending 2025-06-30, TTNP had -$28K decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-06-30 |
|---|---|
| Other | 0 |
| Net loss | -1,252 |
| Prepaid expenses and other current assets | 75 |
| Other accrued liabilities | -236 |
| Notes receivable | 0 |
| Deferred grant revenue | 0 |
| Receivables | 0 |
| Accounts payable | 16 |
| Depreciation and amortization | 0 |
| Net cash used in operating activities | -1,547 |
| Payments on behalf of related party | 81 |
| Proceeds from issuance of preferred stock | 1,600 |
| Net cash provided by financing activities | 1,519 |
| Net decrease in cash | -28 |
TITAN PHARMACEUTICALS INC (TTNP)
TITAN PHARMACEUTICALS INC (TTNP)